TY  - GENERIC
DO  - 10.20944/preprints202102.0068.v1
UR  - http://dx.doi.org/10.20944/preprints202102.0068.v1
TI  - Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer in the United States
T2  - Preprints
AU  - Liu, Qiao
AU  - Luo, Xia
AU  - Peng, Liubao
AU  - Yi, Lidan
AU  - Wan, Xiaomin
AU  - Li, Jianhe
AU  - Zeng, Xiaohui
AU  - Tan, Chongqing
PY  - 2021
DA  - 2021/02/01
PB  - Preprints